Home › Calculator › OPK Dividend Calculator 2026
OPK Dividend DRIP Calculator 2026
148.15% YieldHealthcareOPKO Health, Inc. · NASDAQ
Price: $1.35 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When OPK pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your OPK snowball 📈
$10,000 in OPK → $32988388795679.44M in 10 years · $2,747,221,487,038,633,500.00/month
About OPKO Health, Inc. (OPK) — Dividend Analysis 2026
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Compare OPK with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full OPK DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OPK position with:
🌍 OPK Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold OPK.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 125.93% | 123.13% | $12,593 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 118.52% | 115.72% | $11,852 / yr |
| 🇬🇧 UK ISA | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇬🇧 UK Taxable | 8.75% | 135.19% | 132.39% | $13,519 / yr |
| 🇨🇦 TFSA | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇨🇦 CA Taxable | 25% | 111.11% | 108.31% | $11,111 / yr |
| 🇦🇺 Super (pension) | 15% | 125.93% | 123.13% | $12,593 / yr |
| 🇦🇺 AU Taxable | 30% | 103.70% | 100.91% | $10,371 / yr |
| 🇩🇪 DE Taxable | 26.375% | 109.08% | 106.28% | $10,908 / yr |
| 🇫🇷 FR Taxable | 30% | 103.70% | 100.91% | $10,371 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 OPK Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 OPK Dividend Payment Schedule
OPK pays quarterly — 4 times per year. Next ex-div: TBD.
📊 OPK vs Healthcare Benchmarks
How OPK compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OPK sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ OPK Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-18 | 30,000 | $1.42 | $42.6K | ||
| A-Award | 2026-06-18 | 30,000 | $1.42 | $42.6K | ||
| A-Award | 2026-06-18 | 30,000 | $1.42 | $42.6K | ||
| A-Award | 2026-06-18 | 60,000 | $1.42 | $85.2K | ||
| A-Award | 2026-06-18 | 80,000 | $1.42 | $113.6K | ||
| A-Award | 2026-06-18 | 30,000 | $1.42 | $42.6K | ||
| Buy | 2026-03-20 | 10,000 | $1.14 | $11.3K | ||
| A-Award | 2026-03-18 | 50,000 | $1.17 | $58.5K | ||
| Buy | 2025-11-21 | 192,870 | $1.33 | $257.5K | ||
| Buy | 2025-11-21 | 191,490 | $1.33 | $254.7K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where OPK earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OPK dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
OPKO Health, Inc. (OPK) is currently trading at $1.35, 77% below its 52-week high. The current dividend yield is 148.15% based on an annual payout of $2.00 per share.
OPK (OPKO Health, Inc.) — 148.15% Dividend Yield Analysis
OPKO Health, Inc. (OPK) is a healthcare stock currently trading at $1.35 with a dividend yield of 148.15%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (148.15%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.